Abstract
Oncogenic tyrosine kinases play a ever growing role in the pathogenesis of human malignancies. In human non-hodgkin lymphomas, the NPM-ALK oncogene arising from the t(2;5) chromosomal translocation represents the most important oncogenic tyrosine kinase identified so far. The ALK-kinase is constitutively activated by NPM-induced dimerization and signals through a multitude of growth promoting and antiapoptotic pathways. Murine models have made a significant impact on the elucidation of the molecular pathogenesis and new treatment options of malignant diseases. Here, the latest developments in the analysis of NPM-ALK induced lymphomagenesis by murine models is reviewed.
Keywords: oncoprotein, NPM ALK-protein expression, malignancy, CD 30, xenograft model
Current Drug Targets
Title: Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options
Volume: 7 Issue: 10
Author(s): Cornelius Miething, Christian Peschel and Justus Duyster
Affiliation:
Keywords: oncoprotein, NPM ALK-protein expression, malignancy, CD 30, xenograft model
Abstract: Oncogenic tyrosine kinases play a ever growing role in the pathogenesis of human malignancies. In human non-hodgkin lymphomas, the NPM-ALK oncogene arising from the t(2;5) chromosomal translocation represents the most important oncogenic tyrosine kinase identified so far. The ALK-kinase is constitutively activated by NPM-induced dimerization and signals through a multitude of growth promoting and antiapoptotic pathways. Murine models have made a significant impact on the elucidation of the molecular pathogenesis and new treatment options of malignant diseases. Here, the latest developments in the analysis of NPM-ALK induced lymphomagenesis by murine models is reviewed.
Export Options
About this article
Cite this article as:
Miething Cornelius, Peschel Christian and Duyster Justus, Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559229
DOI https://dx.doi.org/10.2174/138945006778559229 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells
Current Pharmaceutical Biotechnology Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Targeting Signal Transduction Pathways in the Treatment of Mood Disorders: Recent Insights into the Relevance of the Wnt Pathway
CNS & Neurological Disorders - Drug Targets Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Molecular Analysis of Primary Central Nervous System and Primary Intraocular Lymphomas.
Current Molecular Medicine Th17 Cells in Airway Diseases
Current Molecular Medicine Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials Expression of Histone Acetyltransferase GCN5 and Histone Deacetylase 1 in the Cultured Mouse Preimplantation Embryos
Current Pharmaceutical Design Target Fishing of Calactin, Calotropin and Calotoxin Using Reverse Pharmacophore Screening and Consensus Inverse Docking Approach
Current Drug Discovery Technologies